Diagnosis of HER2 gene amplification in breast carcinoma. The genetic point of view;Diagnostic de l'amplification du gène HER2 dans les cancers du sein. Le point de vue génétique

Pathologie Biologie

Volumn 56, Issue 6, 2008, Pages 375-379

  Couturier, J ^a   Vincent Salomon, A ^a   Mathieu, M C ^b   Valent, A ^b   Bernheim, A ^b  

^a INSTITUT CURIE   (France)

^b INSTITUT GUSTAVE ROUSSY   (France)

Author keywords

Amplification; Breast; Carcinoma; FISH; HER2

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; TUMOR MARKER;

ANEUPLOIDY; ARTICLE; BREAST CARCINOMA; CENTROMERE; CLINICAL PRACTICE; CLUSTER ANALYSIS; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; GENE OVEREXPRESSION; HER2 GENE; HUMAN; PROTEIN EXPRESSION; TUMOR GENE;

ANEUPLOIDY; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CENTROMERE; CHROMOSOMES, HUMAN, PAIR 17; FEMALE; GENE AMPLIFICATION; GENE DOSAGE; GENES, ERBB-2; GENETIC PREDISPOSITION TO DISEASE; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE;

EID: 50949101259     PISSN: 03698114     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.patbio.2008.03.009     Document Type: Article

References (23)

1. Slamon D.J., Clark G.M., Wong S.G., Levin W.J., Ullrich A., and McGuire W.L. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235 (1987) 177-182
2. Jacobs T.W., Gown A.M., Yaziji H., Barnes M.J., and Schnitt S.J. Comparison of fluorescence in situ hybridization and immunohistochemistry for the evaluation of HER-2/neu in breast cancer. J Clin Oncol 17 (1999) 1974-1982
3. Couturier J., Vincent-Salomon A., Nicolas A., Beuzeboc P., Mouret E., Zafrani B., et al. Strong correlation between results of fluorescent in situ hybridization and immunohistochemistry for the assessment of the ERBB2 (HER-2/neu) gene status in breast carcinoma. Mod Pathol 13 (2000) 1238-1243
4. Pauletti G., Dandekar S., Rong H., Ramos L., Peng H., Seshadri R., et al. Assessment of methods for tissue-based detection of the HER-2/neu alteration in human breast cancer: a direct comparison of fluorescence in situ hybridization and immunohistochemistry. J Clin Oncol 18 (2000) 3651-3664
5. Slamon D.J., Leyland-Jones B., Shak S., Fuchs H., Paton V., Bajamonde A., et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344 (2001) 783-792
6. Piccart-Gebhart M.J., Procter M., Leyland-Jones B., Goldhirsch A., Untch M., Smith I., et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 353 16 (Oct 20; 2005) 1659-1672
7. Romond E.H., Perez E.A., Bryant J., Suman V.J., Geyer Jr. C.E., Davidson N.E., et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 353 16 (Oct 20; 2005) 1673-1684
8. Wolff A.C., Hammond E.H., Schwartz J.N., Hagerty K.L., Allred D.C., Cote R.J., et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 25 (2007) 118-145
9. Paik S., Bryant J., Tan-Chiu E., Romond E., Hiller W., Park K., et al. Real-world performance of HER2 testing - National Surgical Adjuvant Breast and Bowel Project experience. J Natl Cancer Inst 94 (2002) 852-854
10. Bernheim A., Huret J.L., Guillaud-Bataille M., Brison O., Couturier J., and Groupe français de cytogénétique oncologique. De la cytogénétique à la cytogénomique des tumeurs : le point en 2004. Bull Cancer 91 (2004) 29-43
11. Albertson D.G. Gene amplification in cancer. Trends Genet 22 (2006) 447-455
12. Bernardino J., Gerbault-Seureau M., Zafrani B., Dericke Y., Boudou E., Magdelenat H., et al. Homogeneously staining regions in 223 breast carcinomas: cytogenetic and clinicopathological correlations. Br J Cancer 78 (1998) 1214-1218
13. Bartlett J.M., Going J.J., Mallon E.A., Watters A.D., Reeves J.R., Stanton P., et al. Evaluating HER2 amplification and overexpression in breast cancer. J Pathol 195 (2001) 422-428
14. Downs-Kelly E., Yoder B.J., Stoler M., Tubbs R.R., Skacel M., Grogan T., et al. The influence of polysomy 17 on HER2 gene and protein expression in adenocarcinoma of the breast: a fluorescent in situ hybridization, immunohistochemical, and isotopic mRNA in situ hybridization study. Am J Surg Pathol 29 (2005) 1221-1227
15. Dal Lago L., Durbecq V., Desmedt C., Salgado R., Verjat T., Lespagnard L., et al. Correction for chromosome 17 is critical for the determination of true Her-2/neu gene amplification status in breast cancer. Mol Cancer Ther 5 (2006) 2572-2579
16. Dresser L.G., Seamer L.C., Owens M.A., Clark G.M., and McGuire W.L. DNA flow cytometry and prognostic factors in 1331 frozen breast cancer specimens. Cancer 61 (1988) 420-427
17. Martinez-Arribas F., Nunez-Villar M.J., Lucas A.R., Sanchez J., Tejerina A., and Schneider J. The S-phase fraction of the aneuploid cell subpopulation is the biologically relevant one in aneuploid breast cancers. Breast Cancer Res Treat 92 (2005) 77-80
18. Penault-Llorca F., and Cayre A. Actualité des tests HER2 dans le cancer du sein. Bull Cancer 91 (2004) 211-215
19. Vincent-Salomon A., MacGrogan G., Couturier J., Arnould L., Denoux Y., and Fiche M. Calibration of immunohistochemistry for assessment of HER2 in breast cancer: results of the French multicentre GEFPICS study. Histopathology 42 (2003) 337-347
20. Perez E.A., Roche P.C., Jenkins R.B., Reynolds C.A., Halling K.C., Ingle J.N., et al. HER2 testing in patients with breast cancer: poor correlation between weak positivity by immunohistochemistry and gene amplification by fluorescence in situ hybridization. Mayo Clin Proc 77 (2002) 148-154
21. Isola J., Tanner M., Forsyth A., Crooke T.G., Watters A.D., and Bartlett J.M. Interlaboratory comparison of HER-2 oncogene amplification as detected by chromogenic and fluorescence in situ hybridization. Clin Cancer Res 10 (2004) 4793-4798
22. Lal P., Salazar P.A., Hudis C.A., Ladanyi M., and Chen B. HER-2 testing in breast cancer using immunohistochemical analysis and fluorescence in situ hybridization: a single-institution experience of 2,279 cases and comparison of dual-color and single-color scoring. Am J Clin Pathol 121 (2004) 631-636
23. Vera-Roman J.M., and Rubio-Martinez L.A. Comparative assays for the HER-2/neu oncogene status in breast cancer. Arch Pathol Lab Med 128 (2004) 627-633